Latest news

• BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial

  Results presented at EHA2021 virtual congress showed an improved overall response rate for Brukinsa of 78.3%. ... Of these patients, 207 were on Brukinsa treatment and 208 were on Imbruvica treatment.

• FDA priority review granted for BeiGene’s Brukinsa for marginal zone lymphoma

  The FDA submission for Brukinsa in MZL includes results from the phase 2 MAGNOLIA trial. ... The FDA submission for Brukinsa in MZL includes results from the phase 2 MAGNOLIA trial in patients with relapsed or refractory MZL.

• FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

  Other treatment options for advanced MCL include BeiGene’s recently approved BTK inhibitor Brukinsa (zanubrutinib) and AbbVie/Johnson &Johnson’s established BTK inhibitor Imbruvica (ibrutinib).

• BeiGene’s Brukinsa misses the mark in head-to-head Imbruvica trial

  Brukinsa was unable to demonstrate statistically significant superiority in complete response (CR) or very good partial response (VGPR) rates compared to Imbruvica. ... Although, BeiGene has said that Brukinsa demonstrated numerically higher VGPR rates,

• AstraZeneca’s Calquence impresses in previously untreated CLL

  However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy  Brukinsa (zanubrutinib).